Miraculins and Alere Shift Focus of Endoglin Program from Sub-License to Supply Agreement

Miraculins and Alere Shift Focus of Endoglin Program from Sub-License to Supply 
Agreement 
WINNIPEG, MANITOBA -- (Marketwired) -- 01/30/14 -- Miraculins Inc.
(TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for unmet
clinical needs, announces today that Alere Inc. ("Alere") has elected
not to proceed further in the direct commercial development of a
professional diagnostic product for the biomarker Endoglin, but
instead will support Miraculins in seeking commercialization
opportunities for Endoglin by supplying key antibodies that were
developed by Alere. As part of this decision, Alere has declined to
proceed further with its Endoglin license from Miraculins and the
parties have agreed to work to enhance Miraculins' rights to receive
a secure supply of high quality, proprietary Endoglin reagents
manufactured by Alere. 
Throughout the collaborative development program, Miraculins has
maintained the right to pursue complimentary commercial strategies
for the Endoglin biomarker, which have included the rights to supply
reagents for a Lab Developed Test ("LDT"). LDTs are in vitro
diagnostic tests that are developed, validated and used for in-house
pathology and diagnostic purposes. Tests can either be marketed as a
kit through the FDA's risk-based review process, or they can be sold
to the market as a testing service under LDT definition, with the lab
falling under Clinical Laboratory Improvement Amendments (CLIA)
regulation. The LDT pathway can be a much quicker way to introduce a
test to the market. 
There is a growing body of scientific research, including multiple
research and clinical studies conducted by Alere, confirming that
Endoglin contributes to the pathogenesis of preeclampsia. As the LDT
route now presents the greatest potential near-term commercialization
pathway for Endoglin, Miraculins plans to focus on advancing
discussions with potential partners who have expertise and
capabilities in this space, with full support from Alere. 
"The potential for Endoglin to play a role in assessment of risk or
diagnosis of the devastating condition of preeclampsia remains
promising, and we are pleased that Alere remains committed to work
with us in developing a market for Endoglin testing by making their
proprietary GMP grade Endoglin antibodies available for
distribution," commented Christopher J. Moreau, President and CEO of
Miraculins Inc. 
Currently, preeclampsia affects three million mothers worldwide every
year and is associated with premature births, infant illness
including cerebral palsy, blindness, epilepsy, deafness, lung
conditions, seizure, coma and death. There is no effective detection
method to determine the risk of developing preeclampsia and the cause
is unknown. It is estimated that preeclampsia costs the global health
care system US$3 billion per year. 
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are typically
involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) POC Test is a revolutionary
new coronary artery disease risk assessment technology that measures
cholesterol levels in a patient's skin non-invasively, painlessly and
without the need for fasting. The Company's Scout DS(R) system is the
first non-invasive diabetes testing system designed to provide a
highly sensitive and convenient method for measuring diabetes related
biomarkers in the skin, the accumulation of which are accelerated by
abnormal blood sugar levels and oxidative stress. Unlike current
testing methods, a Scout DS(R) test requires no blood draw, no
fasting, and no waiting for a lab result. The product has been used
and validated in thousands of patients around the world. The
Company's preeclampsia program is partnered with Alere Inc., one of
the world's largest diagnostic companies. For more information visit
www.miraculins.com. 
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release. 
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe", "anticipate",
"expect", "intend", "plan", "will", "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements. 
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully consider the foregoing factors and other
uncertainties and potential events. 
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement. 
PreVu(R) and Scout DS(R) are registered trademarks of Miraculins Inc.
All Rights Reserved. 2014.
Contacts:
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com
 
 
Press spacebar to pause and continue. Press esc to stop.